Beijing Kawin Technology Adjusts Valuation Amidst Mixed Financial Performance Trends

Beijing Kawin Technology Share-Holding Co., Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a shift in the company's valuation metrics, which now indicate a fair standing compared to previous assessments. Key financial indicators reveal a P/E ratio of 32, alongside a price-to-book value of 2.56. The enterprise value to EBITDA stands at 29.85, while the EV to EBIT is noted at 39.97. The PEG ratio is reported at 5.37, and the dividend yield is at 0.72%. Return on capital employed (ROCE) is recorded at 6.39%, with return on equity (ROE) at 7.91%. The company has experienced a modest annual growth rate in net sales of 2.63% and an operating profit growth of 14.42% over the past five years. However, recent financial performance has shown negative trends, particularly in the quarter ending September 2025, which has contributed to the overall evaluation adjustment. For more insights on the latest financial trends and performance metrics, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.